|
ES2590912T3
(es)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
|
|
AU4057300A
(en)
|
1999-03-30 |
2000-10-16 |
Board Of Regents, The University Of Texas System |
Compositions and methods for modifying toxic effects of proteinacious compounds
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
AU778611B2
(en)
|
1999-08-09 |
2004-12-16 |
Merck Patent Gmbh |
Multiple cytokine-antibody complexes
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
ATE336514T1
(de)
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
|
EP1935431A3
(en)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Cancer treatments by using a combination of an antibody against her2 and interleukin-2
|
|
US6689353B1
(en)
*
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
ATE368475T1
(de)
|
2000-06-29 |
2007-08-15 |
Emd Lexigen Res Ct Corp |
Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
|
|
MY139948A
(en)
*
|
2000-09-28 |
2009-11-30 |
Bayer Corp |
Enhanced transfection system
|
|
US7723102B2
(en)
*
|
2000-09-28 |
2010-05-25 |
Bayer Corporation |
Enhanced transfection system
|
|
BR0207854A
(pt)
|
2001-03-07 |
2004-08-24 |
Merck Patent Gmbh |
Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
DK1383785T3
(da)
|
2001-05-03 |
2011-05-23 |
Merck Patent Gmbh |
Rekombinant tumorspecifikt antistof og anvendelse deraf
|
|
PT1454138E
(pt)
|
2001-12-04 |
2012-03-28 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
DK1572748T3
(da)
|
2002-12-17 |
2010-08-23 |
Merck Patent Gmbh |
Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
DE602004031681D1
(de)
|
2003-07-21 |
2011-04-14 |
Transgene Sa |
Multifunktionelle Cytokine
|
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
|
RS53073B
(sr)
|
2003-11-04 |
2014-04-30 |
Novartis Vaccines And Diagnostics Inc. |
Upotreba antagonističkih anti-cd40 monoklonska antitela
|
|
EP1718670B1
(en)
*
|
2004-02-27 |
2011-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity
|
|
AU2005227263A1
(en)
*
|
2004-03-05 |
2005-10-06 |
Novartis Vaccines And Diagnostics, Inc. |
In vitro test system for predicting patient tolerability of therapeutic agents
|
|
WO2009061853A2
(en)
*
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
CN101244261B
(zh)
*
|
2008-03-10 |
2010-09-15 |
山东大学 |
一种含未复性重组蛋白的生物制剂及其制备方法与应用
|
|
DE102008023820A1
(de)
*
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
CN102101885B
(zh)
*
|
2010-09-01 |
2013-06-05 |
南京发士达生物科技有限公司 |
低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
KR20200070407A
(ko)
|
2010-11-12 |
2020-06-17 |
넥타르 테라퓨틱스 |
Ｉｌ-2 부분 및 중합체의 접합체
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
LT3075745T
(lt)
|
2011-02-10 |
2018-11-26 |
Roche Glycart Ag |
Mutavę interleukino-2 polipeptidai
|
|
WO2012119093A1
(en)
*
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
PE20161324A1
(es)
|
2014-02-06 |
2016-11-25 |
Hoffmann La Roche |
Proteinas de fusion de interleucina-2 y usos de las mismas
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
EP3482766B1
(en)
*
|
2014-08-11 |
2020-05-20 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
US12233104B2
(en)
|
2015-10-08 |
2025-02-25 |
Nektar Therapeutics |
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
KR20240115933A
(ko)
*
|
2016-05-04 |
2024-07-26 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
CN109689694B
(zh)
*
|
2016-05-19 |
2022-11-22 |
通用医疗公司 |
与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台
|
|
BR112018076260A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
EP3475413B1
(en)
*
|
2016-06-22 |
2024-02-14 |
David Klatzmann |
Genetically modified t lymphocytes
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
CN110167957A
(zh)
|
2016-11-08 |
2019-08-23 |
德里尼亚公司 |
用于治疗自身免疫疾病的il-2变体
|
|
WO2018112069A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Delinia, Inc. |
Multivalent regulatory t cell modulators
|
|
JP7165717B2
(ja)
|
2017-03-15 |
2022-11-04 |
パンディオン・オペレーションズ・インコーポレイテッド |
標的免疫寛容
|
|
JOP20190271A1
(ar)
*
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
IL322309A
(en)
|
2017-05-24 |
2025-09-01 |
Novartis Ag |
IL2 antibody grafted proteins and methods of use in cancer treatment
|
|
MX2019013517A
(es)
|
2017-05-24 |
2020-08-17 |
Pandion Operations Inc |
Inmunotolerancia dirigida.
|
|
US20200362058A1
(en)
*
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
EP3641814A4
(en)
|
2017-06-19 |
2021-06-23 |
Medicenna Therapeutics Inc. |
USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF
|
|
US20200181220A1
(en)
*
|
2017-08-03 |
2020-06-11 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
|
WO2019104092A1
(en)
|
2017-11-21 |
2019-05-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
|
EP3752178A1
(en)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
US11359000B2
(en)
|
2018-03-28 |
2022-06-14 |
Bristol-Myers Squibb Company |
Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
|
|
MA52662A
(fr)
|
2018-03-28 |
2021-02-17 |
Ascendis Pharma Oncology Div A/S |
Conjugués d'il-2
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
CA3106858A1
(en)
*
|
2018-07-24 |
2020-01-30 |
Biontech Rna Pharmaceuticals Gmbh |
Il2 agonists
|
|
US12403181B2
(en)
|
2018-08-13 |
2025-09-02 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
US11492384B2
(en)
*
|
2018-09-17 |
2022-11-08 |
Gi Innovation, Inc. |
Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
|
|
JP7512210B2
(ja)
|
2018-09-21 |
2024-07-08 |
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド |
新規インターロイキン２およびその使用
|
|
JP7543269B2
(ja)
|
2018-12-21 |
2024-09-02 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
ヒトインターロイキン２の変異体またはその誘導体
|
|
EP3972992A4
(en)
|
2019-05-20 |
2023-07-19 |
Pandion Operations, Inc. |
MADCAM TARGETED IMMUNOTLERANCE
|
|
TW202115105A
(zh)
*
|
2019-06-24 |
2021-04-16 |
德商拜恩迪克Ｒｎａ製藥有限公司 |
Ｉｌ２激動劑
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
PH12022550326A1
(en)
*
|
2019-08-13 |
2023-03-13 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
KR20220139293A
(ko)
|
2019-12-12 |
2022-10-14 |
일투 파마 |
인터류킨 2 키메라 구축물
|
|
JP7755581B2
(ja)
|
2019-12-17 |
2025-10-16 |
アムジエン・インコーポレーテツド |
治療における使用のためのデュアルインターロイキン－２／ｔｎｆ受容体アゴニスト
|
|
WO2021140416A2
(en)
|
2020-01-10 |
2021-07-15 |
Bright Peak Therapeutics Ag |
Modified il-2 polypeptides and uses thereof
|
|
AU2021207661A1
(en)
*
|
2020-01-14 |
2022-07-21 |
Synthekine, Inc. |
IL2 muteins
|
|
US11491205B2
(en)
|
2020-01-14 |
2022-11-08 |
Synthekine, Inc. |
Biased IL2 muteins methods and compositions
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
CA3175717A1
(en)
|
2020-03-19 |
2021-09-23 |
Innovent Biologics (Suzhou) Co., Ltd. |
Interleukin-2 mutant and use thereof
|
|
PE20221759A1
(es)
|
2020-03-31 |
2022-11-11 |
Hanmi Pharm Ind Co Ltd |
Nuevos analogos de il-2 inmunoestimuladores
|
|
IL298642A
(en)
|
2020-06-03 |
2023-01-01 |
Ascendis Pharma Oncology Div A/S |
il-2 sequences and uses thereof
|
|
WO2022094275A1
(en)
|
2020-10-29 |
2022-05-05 |
Bristol-Myers Squibb Company |
Fusion proteins for the treatment of disease
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
EP4255466A1
(en)
|
2020-12-04 |
2023-10-11 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
CN113308477A
(zh)
*
|
2021-04-08 |
2021-08-27 |
华南农业大学 |
一种鸭il-2基因真核表达重组质粒及其制备方法
|
|
IL311643A
(en)
|
2021-09-22 |
2024-05-01 |
Fortvita Biologics Singapore Pte Ltd |
Interleukin-2 mutant and fusion protein
|
|
MX2024004291A
(es)
|
2021-10-06 |
2024-06-28 |
Iltoo Pharma |
Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados.
|
|
CN114875069B
(zh)
*
|
2022-04-22 |
2023-09-15 |
四川大学 |
基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
|
|
KR20250039519A
(ko)
*
|
2022-06-16 |
2025-03-20 |
세파론 엘엘씨 |
항-pd-1 항체-약화된 il-2 면역접합체 및 그의 용도
|
|
CA3265946A1
(en)
|
2022-09-12 |
2024-03-21 |
Univ Sorbonne |
INTERLEUKIN-2 FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS
|
|
FR3140287B1
(fr)
|
2022-10-03 |
2025-11-21 |
Arkema France |
Procede de granulation de composes azoiques et granules obtenus
|
|
WO2024103860A1
(zh)
|
2022-11-18 |
2024-05-23 |
南京诺艾新生物技术有限公司 |
受体亲和力偏好性的定点偶联聚乙二醇化白介素-2突变体及其用途
|